Losacard 25 mg (Tablet)
Unit Price: ৳ 4.51 (30's pack: ৳ 135.27)
Medicine Details
| Category | Details |
|---|---|
| Generic | Losartan potassium |
| Company | Novo healthcare and pharma ltd |
| Also available as |
Indications
- Treatment of hypertension
- Renal protection in type-2 diabetic patients with proteinuria
Pharmacology
- First non-peptide orally active angiotensin II receptor blocker
- Binds to the AT1 receptor in various tissues
Dosage & Administration
- Usual starting and maintenance dose of 50 mg once daily
- Can be administered once or twice daily
- Total daily dose ranges from 25 mg to 100 mg
- Different initial dosage adjustments for patients upto 75 years and over 75 years
Interaction
- Reduction of active metabolite levels by rifampicin and fluconazole
- Potentiation of antihypertensive effects with hydrochlorothiazide
- Potential increases in serum potassium with potassium-sparing diuretics and supplements
- Possible attenuation of antihypertensive effect by non-steroidal anti-inflammatory drug indomethacin
- Increased risk of renal impairment with concurrent use of ACE-inhibitor, angiotensin receptor antagonist, anti-inflammatory drug, and thiazide diuretic
Contraindications
- Contraindicated in pregnant women
- Contraindicated in patients hypersensitive to any component of the product
- Should not be administered with aliskiren in patients with diabetes
Side Effects
- Mild and transient side effects
- Common side effects include dizziness, diarrhea, nasal congestion, cough, and upper respiratory infection
- Other side effects include fatigue, edema, abdominal pain, chest pain, nausea, headache, and pharyngitis
Pregnancy & Lactation
- Pregnancy Category D
- Risk to the fetus increases if administered during the second or third trimesters
- Uncertain excretion in human milk
- Consideration needed for nursing mothers
Precautions & Warnings
- Reduces fetal renal function and increases fetal and neonatal morbidity and death when used during the second and third trimesters of pregnancy
- Possible symptomatic hypotension in intravascularly volume-depleted patients
- Significantly increased plasma concentration in cirrhotic patients
- Changes in renal function including renal failure reported in renal impaired patients
Use in Special Populations
- No initial dosage adjustment needed in patients with mild renal impairment
- Lower starting dose recommended for patients with moderate to severe renal impairment or on dialysis
- Lower dose consideration for patients with a history of hepatic impairment
Therapeutic Class
- Angiotensin-II receptor blocker
Storage Conditions
- Keep in a dry place away from light and heat
- Keep out of the reach of children